Clinical Trials Logo

Embolization clinical trials

View clinical trials related to Embolization.

Filter by:
  • None
  • Page 1

NCT ID: NCT06095050 Not yet recruiting - Shoulder Pain Clinical Trials

Embolization Treatment of Chronic Refractory Shoulder Tendinopathy

ELECTRC
Start date: December 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized controlled trial in which patients with moderate to severe shoulder pain (Visual Analog Scale (VAS) > 40), in the setting of rotator cuff tendinopathy refractory to conservative treatment, will be enrolled. The primary aim of the study is to estimate the effect of transcatheter arterial embolization (TAE) with physical therapy (PT) vs PT alone on the change in shoulder pain at 12-month follow up. Scientific objectives also include an assessment of safety of the intervention, assessment of changes in Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity score, Shoulder Pain and Disability Index (SPADI) scores, MRI Tendinopathy Score between the TAE + PT and PT groups.

NCT ID: NCT05633134 Not yet recruiting - Pelvic Tumor Clinical Trials

Precision Preoperative Embolization of Pelvic Tumors to Improve Surgical Outcomes

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The main purpose of this study is to assess the efficacy of precision preoperative embolization in decreasing operative blood loss, reducing surgical complications in pelvic tumor surgery. Furthermore the study aims at describing the vascularity in a series of pelvic tumors, and to correlate this with perioperative blood loss.

NCT ID: NCT05629130 Recruiting - Hemophilia Clinical Trials

Embolization in Hereditary Coagulopathies

EHCO
Start date: January 16, 2023
Phase: N/A
Study type: Interventional

This is a longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and/or ankles followed up at the Centro de Hemofilia HCFMUSP, after approval by the ethics and research committee. They will undergo imaging tests (X-rays and Magnetic Resonance of knee, elbow, or ankle), physical, pain, quality of life and functional assessments (Hemophilia Joint Health Score, Functional Independence Score in Hemophilia, Perimeter, Test Timed up and Go, 30 second sit and stand test, Haemophilia - Adult - Quality of Life questionnaire (HAEM-A-QoL), Knee Injury and Osteoarthritis Outcome Score, EQ-5D, numerical rating scale for pain and embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France), until partial vascular stasis and decharacterization of pathological synovial enhancement. These evaluations will be performed at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months after the procedure.

NCT ID: NCT05361161 Not yet recruiting - Gastric Cancer Clinical Trials

Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC)

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, open-labelled study to evaluate the efficacy and safety of sequential transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of Initial unresectable gastric cancer.

NCT ID: NCT03740321 Recruiting - Hemorrhoids Clinical Trials

SRAE With Embospheres for Hemorrhoids.

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

In this study , safety and efficacy of superior rectal artery embolization with embospheres will be researched prospectively.

NCT ID: NCT03072446 Completed - Uterine Fibroid Clinical Trials

Uterine Fibroid Embolization (UFE) for Symptomatic Fibroids: Comparison of Gel-Bead to Commonly Used Embolic Agents.

Start date: April 24, 2017
Phase: N/A
Study type: Interventional

The purpose of this post-market study is to evaluate UFE agents for the treatment of symptomatic uterine fibroids, using Gel-Bead compared to four other commonly used embolic agents.